Trial intelligence / Profile preview

Cisplatin and Metronomic Cyclophosphamide in Metastatic TNBC

NCT01910844Phase 2Terminated

Sponsor
Centre Jean Perrin
Start
Jul 2013
Primary completion
Sep 2016
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of cisplatin, cyclophosphamide in triple-negative breast cancer (TNBC), sponsored by Centre Jean Perrin. Started Jul 2013; status: terminated.

02

Drugs

cisplatincyclophosphamide
03

Conditions

triple-negative breast cancer (TNBC)

Beyond the preview

Go deeper on NCT01910844.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01910844.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call